28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: SAGE-718
DRUG: Placebo

Sponsor

Supernus Pharmaceuticals, Inc.